- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02491541
A Phase 3 Clinical Trial for a Rabies Vaccine (Vero Cell) for Human Use in Healthy Chinese Subjects
July 8, 2015 updated by: Jiangsu Province Centers for Disease Control and Prevention
A Single-centre, Randomized, Double-blind, Parallel Control, Phase 3 Study to Evaluate the Safety and Immunogenicity of a Rabies Vaccine (Vero Cell) for Human Use in Healthy Chinese Subjects Aged 10-60 Years
The purpose of this single-centre, randomized, double-blind, parallel control, phase 3 study is to evaluate the safety and immunogenicity of a rabies vaccine (Vero Cell) for human use in healthy Chinese subjects aged 10-60 years, according to the Essen methods (1-1-1-1-1) vaccination.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
There will be two immunization arms.
1200 healthy subjects will be randomly assigned (1:1) to receive an experimental vaccine or a parallel comparator vaccine.
All of them will be received five doses of rabies vaccine at day 0,3,7,14,28 according to the traditional Essen methods (1-1-1-1-1) vaccination.
Study Type
Interventional
Enrollment (Actual)
1200
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Jiangsu
-
Xuzhou, Jiangsu, China, 221400
- Xinyi Center for Disease Control and Prevention
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
10 years to 60 years (Child, Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Aged from 10 to 60 years old
- Subjects or legal guardians can and will comply with the requirements of the protocol
- Subjects or legal guardians are able to understand and sign the informed consent
- Healthy subjects judged from medical history after investigator's inquiry
- Subjects with temperature <=37.0°C on axillary setting
Exclusion Criteria:
- Female in lactation or pregnancy, or plan to be pregnant during the study period
- Subject who has allergic history to any vaccine or other medicines
- Subject who has injury history by dogs or other mammals and has been vaccinated with rabies vaccine
- Subject who has serious adverse reaction history after vaccination such as allergies, hives, difficulty in breathing, angioedema or abdominal pain
- Subject with congenital malformation, developmental disorder or serious chronic disease
- Subject with autoimmune diseases or immunodeficiency
- Subject with asthma, unstable over the past two years requiring emergency treatment, hospitalization, intubation, oral or intravenous corticosteroids
- Subject with diabetes (Type I or II) excluding gestational diabetes
- Subject with thyroidectomy history, or require treatment in the past 12 months due to thyroid disease
- Subject with severe angioedema in the past 3 years or require treatment in the past 2 years
- Subject with hypertension and with a blood pressure exceeding 145/95 mmHg at enrollment time
- Subject with coagulation abnormalities diagnosed by doctors (such as clotting factor deficiency, coagulation disorders, platelet disorder) or obvious bruises or blood clotting disorder
- Subject with cancer, or has been treated in active cancer period or not clearly cured, or may recur during the study period
- Subject with epilepsy, excluding those alcohol epilepsy within three years before quitting drinking or those do not need treatment in the past 3 years
- Asplenia, functional asplenia, without a spleen or removal of the spleen caused by any situation
- Guillain-Barre syndrome
- Any prior administration of immunodepressant or corticosteroids in last 6 months
- Any prior administration of blood products in last 3 months
- Any prior administration of other research medicine/vaccine in last 30 days
- Any prior administration of any attenuated live vaccine in last 30 days
- Any prior administration of subunit or inactivated vaccines in last 14 days, such as pneumococcal vaccine
- Ongoing anti-tuberculosis prevention or treatment
- Subject who cannot comply with the trial requirements, or with mental illness/ dual-stage affective psychosis in the past or at present; or has not been controlled and needs to take psychiatric drugs the past 2 years; or with suicidal tendencies in the past 5 years
- Any medical, psychological, social or other condition judged by investigator, that may interfere subject's compliance with the protocol or signature on informed consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Changchun Werersai
A rabies vaccine (Vero Cell) for human use produced by Changchun Werersai Biotech Pharmaceutical Co., Ltd.
|
A rabies vaccine (Vero Cell) for human use produced by Changchun Werersai Biotech Pharmaceutical Co., Ltd. 1.0 ml experimental vaccine on day 0,3,7,14,28 |
Active Comparator: Jilin Maifeng
A rabies vaccine (Vero Cell) for human use produced by Jilin Maifeng Biotech Pharmaceutical Co., Ltd.
|
A rabies vaccine (Vero Cell) for human use produced by Jilin Maifeng Biotech Pharmaceutical Co., Ltd. 1.0 ml comparator vaccine on day 0,3,7,14,28 |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Positive seroconversion rate of serum rabies virus neutralizing antibody 42 days after full vaccination
Time Frame: 42 days after full vaccination
|
42 days after full vaccination
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Geometric mean concentration (GMC) of serum rabies virus neutralizing antibody 42 days after full vaccination
Time Frame: 42 days after full vaccination
|
42 days after full vaccination
|
Positive seroconversion rate of serum rabies virus neutralizing antibody 14 days after full vaccination
Time Frame: 14 days after full vaccination
|
14 days after full vaccination
|
Geometric mean concentration (GMC) of serum rabies virus neutralizing antibody 14 days after full vaccination
Time Frame: 14 days after full vaccination
|
14 days after full vaccination
|
Incidence of local and systemic adverse reactions during safety observation period after each vaccination
Time Frame: 0-7 days after each vaccination and 8-28 days after the fifth vaccination
|
0-7 days after each vaccination and 8-28 days after the fifth vaccination
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Yuemei Hu, Jiangsu Provincial Center for Diseases Control and Prevention
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2012
Primary Completion (Actual)
December 1, 2012
Study Completion (Actual)
December 1, 2013
Study Registration Dates
First Submitted
July 3, 2015
First Submitted That Met QC Criteria
July 3, 2015
First Posted (Estimate)
July 8, 2015
Study Record Updates
Last Update Posted (Estimate)
July 9, 2015
Last Update Submitted That Met QC Criteria
July 8, 2015
Last Verified
July 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20120002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rabies
-
The Methodist Hospital Research InstituteGrifols Biologicals, LLCCompletedRabies | Rabies Human | Rabies Virus InfectionUnited States
-
The Methodist Hospital Research InstituteGrifols Biologicals, LLCRecruitingRabies | Rabies Human | Pediatrics | Rabies Virus InfectionUnited States
-
Centers for Disease Control and PreventionCompletedRabies Prevention | Rabies ExposureUnited States
-
Changchun Zhuoyi Biological Co., LtdEnrolling by invitation
-
Sanofi Pasteur, a Sanofi CompanyActive, not recruiting
-
Sanofi Pasteur, a Sanofi CompanyCompleted
-
Synermore Biologics Co., Ltd.inVentiv Health ClinicalCompleted
-
Sanofi Pasteur, a Sanofi CompanyCompleted
-
Provincial Public Health Office, PhetchabunCompleted
-
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.Sponsor GmbHCompletedRabies Vaccine Adverse ReactionChina
Clinical Trials on Changchun Werersai
-
Affiliated Hospital of Jiangnan UniversityCompletedGrowth Hormone Treatment | Phelan-McDermid SyndromeChina
-
Nanjing NingQi Medicine Science and Technology...UnknownNon-small Cell Lung CancerChina
-
Sinovac (Dalian) Vaccine Technology Co., Ltd.Enrolling by invitation
-
Shanghai Institute Of Biological ProductsCompleted
-
China National Biotec Group Company LimitedPeking University; Shaanxi Provincial Center for Disease Control and Prevention and other collaboratorsUnknown